Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, a commercial-stage biopharmaceutical company. The acquisition adds Avadel’s FDA-approved product, LUMRYZ, to Alkermes’ commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. The acquisition also includes valiloxybate, Avadel’s in-licensed salt-free, once-at-bedtime oxybate candidate in phase 1 clinical development. This strategic move accelerates Alkermes’ ...